长春高新(000661.SZ)：金赛药业重组人生长激素注射液药品批准证明文件获签发

格隆汇8月4日丨长春高新(000661.SZ)公布，2022年8月4日，国家药监局政务服务门户网站“送达信息”栏《2022年08月04日药品批准证明文件待领取信息发布》信息显示：国家药监局已签发公司控股子公司长春金赛药业有限责任公司重组人生长激素注射液相关药品批准证明文件。

该次申请的重组人生长激素注射液(15IU/5mg/3ml/瓶、30IU/10mg/3ml/瓶、2IU/0.66mg/0.4ml/支、4.5IU/1.5mg/0.9ml/支)为新增用于特发性身材矮小(ISS)相关适应症。

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.